Agenus

  • Bioinformatics Scientist

    Job Locations US-MA-Lexington
    Job ID
    2018-1450
    Category
    Research
  • Overview

    Agenus is expanding a multidisciplinary department with experience in biostatistics, genomics, bioinformatics, biotechnology, next-generation sequencing (NGS), immunology, and molecular biology.  We are searching for a Bioinformatics scientist to focus on analysis, visualization and interpretation of high throughput profiling data, including NGS data. You’ll be part of our team pioneering new ways to look at neoantigens as we seek to cure cancer.

     

    Responsibilities

     

     

    • Analyze and interpret high-throughput internal DNA and RNA sequencing data from Illumina sequencing platforms, with a specific focus on mutation identification and immunological characterization
    • Analyze and interpret external molecular ‘big data’ profiling data, including cancer mutation, gene expression, and immunological data
    • Predict how the immune system recognizes tumor cells
    • Publish results
    • Tight interactions with biotechnology and immunology teams
    • Apply findings in both R&D and clinical projects for biomarkers and immunotherapies

     

     

    Qualifications

     

    • Demonstrated excellence processing and analyzing large NGS datasets
    • Extensive experience developing new software tools
    • Proven statistical skills for data mining
    • Excellent data visualization and communication skills
    • Self-starter who works effectively in an agile start-up environment 
    • Enthusiastic team player

     

    Preferred

    • Experience with cancer and immunologic pathways
    • Familiarity with computational immunology, such as T cell signaling pathways and TCR-peptide-MHC interactions
    • Familiarity with bio-lead structures, including BCRs and TCRs

    EDUCATION 

    • PhD or Masters with +5 years with experience in bioinformatics, biostatistics, or related field

     

     

    Options

    Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
    Share on your newsfeed